Newsroom

We’re excited to share that Dendrogenix will take part in the upcoming Sambrinvest Bio Investment Convention on October 16, 2025, a key event bringing together innovative companies and forward-thinking investors in the Wallonia region. This convention offers a valuable opportunity for us to showcase our progress in developing next-generation neuroprotective and neuroregenerative therapies in the field of Hearing Loss, and to connect with partners who share our vision for transforming patient care. Our team looks forward to engaging discussions on our clinical and strategic milestones, while exploring new avenues for collaboration and investment to fuel the next stage of our growth.

Dr. Quentin Marlier, head of biology at Dendrogenix and ESO member, will present a poster publication entitled “Improvement of neurological outcomes following Stroke in mice treated with a novel first-in-class compound” to expose preclinical data regarding its lead compound DX243 in Stroke. European Stroke Organisation Conference (ESOC) is Europe’s leading forum for advances in research and clinical care of patients with cerebrovascular diseases. ESOC 2025 will take place from 21–23 May 2025 in Helsinki, Finland.

Dendrogenix CEO, CSO and CDO will attend to BioEquity Europe 2025 | May 12–14, 2025 | Bruges, Belgium. Celebrating its 25th year, BioEquity Europe is the destination event for biopharma decision-makers to network, partner and debate critical issues facing the biotech industry.

During the SFN 2024 edition in Chicago, Dr. Quentin Marlier, head of biology at Dendrogenix, will present a poster publication called “Improvement of neurological outcomes following Stroke or traumatic brain injury in mice treated with a novel first-in-class compound” to expose preclinical data regarding its lead compound DX243 in stroke and TBI model.